Scinai Immunotherapeutics Ltd. Financials
This page shows Scinai Immunotherapeutics Ltd. (SCNI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Scinai Immunotherapeutics Ltd. has an operating margin of -1312.8%, meaning the company retains $-1313 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
Scinai Immunotherapeutics Ltd. carries a low D/E ratio of 0.35, meaning only $0.35 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.
Scinai Immunotherapeutics Ltd.'s current ratio of 1.32 indicates adequate short-term liquidity, earning a score of 33/100. The company can meet its near-term obligations, though with limited headroom.
While Scinai Immunotherapeutics Ltd. generated -$6.3M in operating cash flow, capex of $12K consumed most of it, leaving -$6.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Scinai Immunotherapeutics Ltd. earns a strong 48.1% return on equity (ROE), meaning it generates $48 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100.
Scinai Immunotherapeutics Ltd. passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Scinai Immunotherapeutics Ltd. generates $-1.32 in operating cash flow (-$6.3M OCF vs $4.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Scinai Immunotherapeutics Ltd. generated $658K in revenue in fiscal year 2024.
Scinai Immunotherapeutics Ltd.'s EBITDA was -$7.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 24.0% from the prior year.
Scinai Immunotherapeutics Ltd. generated -$6.3M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 36.7% from the prior year.
Scinai Immunotherapeutics Ltd. reported $4.8M in net income in fiscal year 2024. This represents an increase of 173.8% from the prior year.
Scinai Immunotherapeutics Ltd. held $2.0M in cash against $0 in long-term debt as of fiscal year 2024.
Scinai Immunotherapeutics Ltd. had 3.41B shares outstanding in fiscal year 2024. This represents an increase of 83.7% from the prior year.
Scinai Immunotherapeutics Ltd.'s gross margin was -88.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs.
Scinai Immunotherapeutics Ltd.'s operating margin was -1312.8% in fiscal year 2024, reflecting core business profitability.
Scinai Immunotherapeutics Ltd.'s net profit margin was 728.9% in fiscal year 2024, showing the share of revenue converted to profit.
Scinai Immunotherapeutics Ltd.'s ROE was 48.1% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.
Scinai Immunotherapeutics Ltd. invested $5.5M in research and development in fiscal year 2024. This represents an increase of 6.2% from the prior year.
Scinai Immunotherapeutics Ltd. invested $12K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 98.1% from the prior year.
SCNI Income Statement
| Metric | Q2'25 | Q2'24 | Q4'23 | Q2'23 | Q1'23 | Q4'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | $1.5M-27.1% | $2.0M | N/A | $2.0M+69.7% | $1.2M |
| SG&A Expenses | N/A | N/A | N/A | $1.1M-4.2% | $1.2M | N/A | $1.3M-11.2% | $1.5M |
| Operating Income | N/A | N/A | N/A | -$2.6M+18.5% | -$3.2M | N/A | -$3.3M-24.8% | -$2.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A | -$3.8M-7.0% | -$3.5M | N/A | -$3.0M-20.5% | -$2.5M |
| EPS (Diluted) | N/A | N/A | N/A | $-0.000.0% | $-0.00 | N/A | $-0.00-33.3% | $-0.00 |
SCNI Balance Sheet
| Metric | Q2'25 | Q2'24 | Q4'23 | Q2'23 | Q1'23 | Q4'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.8M-12.0% | $13.4M-23.0% | $17.5M-12.2% | $19.9M-14.6% | $23.3M-13.9% | $27.1M | N/A | N/A |
| Current Assets | $1.5M-37.0% | $2.4M-56.1% | $5.4M-29.9% | $7.8M-29.7% | $11.0M-23.1% | $14.4M | N/A | N/A |
| Cash & Equivalents | $989K-49.6% | $2.0M-59.7% | $4.9M-35.1% | $7.5M-30.5% | $10.8M-23.3% | $14.1M+24.7% | $11.3M-26.7% | $15.4M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $139K+67.5% | $83K | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.0M+14.7% | $3.5M-84.3% | $22.0M-18.4% | $27.0M-3.9% | $28.1M-2.5% | $28.8M | N/A | N/A |
| Current Liabilities | $2.1M+17.4% | $1.8M+1.5% | $1.8M-5.7% | $1.9M-26.8% | $2.6M+10.3% | $2.3M | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $7.9M-21.2% | $10.0M+318.4% | -$4.6M+35.8% | -$7.1M-47.9% | -$4.8M-173.3% | -$1.8M-153.9% | $3.3M+478.7% | -$862K |
| Retained Earnings | -$121.7M-3.5% | -$117.5M+3.9% | -$122.3M+0.6% | -$123.1M-3.2% | -$119.3M-3.0% | -$115.8M | N/A | N/A |
SCNI Cash Flow Statement
| Metric | Q2'25 | Q2'24 | Q4'23 | Q2'23 | Q1'23 | Q4'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A | -$2.9M+6.0% | -$3.1M | N/A | -$3.7M-231.7% | -$1.1M |
| Capital Expenditures | N/A | N/A | N/A | $377K+6183.3% | $6K | N/A | -$35K-106.7% | $521K |
| Free Cash Flow | N/A | N/A | N/A | -$3.3M-6.1% | -$3.1M | N/A | -$3.7M-127.6% | -$1.6M |
| Investing Cash Flow | N/A | N/A | N/A | -$377K-6183.3% | -$6K | N/A | $35K+106.7% | -$521K |
| Financing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SCNI Financial Ratios
| Metric | Q2'25 | Q2'24 | Q4'23 | Q2'23 | Q1'23 | Q4'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | -18.9%-3.8pp | -15.1% | N/A | N/A | N/A |
| Current Ratio | 0.71-0.6 | 1.32-1.7 | 3.06-1.1 | 4.12-0.2 | 4.28-1.9 | 6.15 | N/A | N/A |
| Debt-to-Equity | 0.51+0.2 | 0.35+5.2 | -4.82-1.0 | -3.80+2.0 | -5.84+10.5 | -16.38 | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Scinai Immunotherapeutics Ltd.'s annual revenue?
Scinai Immunotherapeutics Ltd. (SCNI) reported $658K in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Scinai Immunotherapeutics Ltd. profitable?
Yes, Scinai Immunotherapeutics Ltd. (SCNI) reported a net income of $4.8M in fiscal year 2024, with a net profit margin of 728.9%.
What is Scinai Immunotherapeutics Ltd.'s EBITDA?
Scinai Immunotherapeutics Ltd. (SCNI) had EBITDA of -$7.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Scinai Immunotherapeutics Ltd.'s gross margin?
Scinai Immunotherapeutics Ltd. (SCNI) had a gross margin of -88.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Scinai Immunotherapeutics Ltd.'s operating margin?
Scinai Immunotherapeutics Ltd. (SCNI) had an operating margin of -1312.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Scinai Immunotherapeutics Ltd.'s net profit margin?
Scinai Immunotherapeutics Ltd. (SCNI) had a net profit margin of 728.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Scinai Immunotherapeutics Ltd.'s return on equity (ROE)?
Scinai Immunotherapeutics Ltd. (SCNI) has a return on equity of 48.1% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Scinai Immunotherapeutics Ltd.'s free cash flow?
Scinai Immunotherapeutics Ltd. (SCNI) generated -$6.3M in free cash flow during fiscal year 2024. This represents a 36.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Scinai Immunotherapeutics Ltd.'s operating cash flow?
Scinai Immunotherapeutics Ltd. (SCNI) generated -$6.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Scinai Immunotherapeutics Ltd.'s total assets?
Scinai Immunotherapeutics Ltd. (SCNI) had $13.4M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Scinai Immunotherapeutics Ltd.'s capital expenditures?
Scinai Immunotherapeutics Ltd. (SCNI) invested $12K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Scinai Immunotherapeutics Ltd. spend on research and development?
Scinai Immunotherapeutics Ltd. (SCNI) invested $5.5M in research and development during fiscal year 2024.
How many shares does Scinai Immunotherapeutics Ltd. have outstanding?
Scinai Immunotherapeutics Ltd. (SCNI) had 3.41B shares outstanding as of fiscal year 2024.
What is Scinai Immunotherapeutics Ltd.'s current ratio?
Scinai Immunotherapeutics Ltd. (SCNI) had a current ratio of 1.32 as of fiscal year 2024, which is considered adequate.
What is Scinai Immunotherapeutics Ltd.'s debt-to-equity ratio?
Scinai Immunotherapeutics Ltd. (SCNI) had a debt-to-equity ratio of 0.35 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Scinai Immunotherapeutics Ltd.'s return on assets (ROA)?
Scinai Immunotherapeutics Ltd. (SCNI) had a return on assets of 35.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Scinai Immunotherapeutics Ltd.'s cash runway?
Based on fiscal year 2024 data, Scinai Immunotherapeutics Ltd. (SCNI) had $2.0M in cash against an annual operating cash burn of $6.3M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Scinai Immunotherapeutics Ltd.'s Piotroski F-Score?
Scinai Immunotherapeutics Ltd. (SCNI) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Scinai Immunotherapeutics Ltd.'s earnings high quality?
Scinai Immunotherapeutics Ltd. (SCNI) has an earnings quality ratio of -1.32x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Scinai Immunotherapeutics Ltd.?
Scinai Immunotherapeutics Ltd. (SCNI) scores 46 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.